Last reviewed · How we verify
Colchicine Pill
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators.
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators. Used for Acute gout flares, Familial Mediterranean fever (FMF), Gout prophylaxis.
At a glance
| Generic name | Colchicine Pill |
|---|---|
| Also known as | Colchicine, Colchicine 0.5 MG, group C |
| Sponsor | Brigham and Women's Hospital |
| Drug class | Microtubule inhibitor / Anti-inflammatory agent |
| Target | Beta-tubulin |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Colchicine binds to beta-tubulin and prevents microtubule assembly, which disrupts cell division and inflammatory cell movement. This mechanism reduces the recruitment of neutrophils and other immune cells to sites of inflammation, and decreases the production of pro-inflammatory cytokines like IL-1β and TNF-α. The drug has been used for centuries in gout and is now approved for acute gout flares and familial Mediterranean fever.
Approved indications
- Acute gout flares
- Familial Mediterranean fever (FMF)
- Gout prophylaxis
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Myopathy
- Peripheral neuropathy
Key clinical trials
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine (PHASE4)
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis (PHASE3)
- Colchicine Versus Placebo in Acute Myocarditis Patients (PHASE3)
- Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment (PHASE2)
- Perioperative Colchicine for TKA (PHASE4)
- Colchicine in Chronic Kidney Disease Patients (PHASE3)
- Efficacy and Safety of Colchicine After PCI (PHASE3)
- Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colchicine Pill CI brief — competitive landscape report
- Colchicine Pill updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI